...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Development of a recombinant fusion protein based on the dynein light chain LC8 for non-viral gene delivery
【24h】

Development of a recombinant fusion protein based on the dynein light chain LC8 for non-viral gene delivery

机译:基于达因轻链LC8的非病毒基因重组重组融合蛋白的开发

获取原文
获取原文并翻译 | 示例
           

摘要

The low efficiency of gene transfer is a recurrent problem in DNA vaccine development and gene therapy studies using non-viral vectors such as plasmid DNA (pDNA). This is mainly due to the fact that during their traffic to the target cell's nuclei, plasmid vectors must overcome a series of physical, enzymatic and diffusional barriers. The main objective of this work is the development of recombinant proteins specifically designed for pDNA delivery, which take advantage of molecular motors like dynein, for the transport of cargos from the periphery to the centrosome of mammalian cells. A DNA binding sequence was fused to the N-terminus of the recombinant human dynein light chain LC8. Expression studies indicated that the fusion protein was correctly expressed in soluble form using E. coli BL21(DE3) strain. As expected, gel permeation assays found the purified protein mainly present as dimers, the functional oligomeric state of LC8. Gel retardation assays and atomic force microscopy proved the ability of the fusion protein to interact and condense pDNA. Zeta potential measurements indicated that LC8 with DNA binding domain (LD4) has an enhanced capacity to interact and condense pDNA, generating positively charged complexes. Transfection of cultured HeLa cells confirmed the ability of the LD4 to facilitate pDNA uptake and indicate the involvement of the retrograde transport in the intracellular trafficking of pDNA:LD4 complexes. Finally, cytotoxicity studies demonstrated a very low toxicity of the fusion protein vector, indicating the potential for in vivo applications. The study presented here is part of an effort to develop new modular shuttle proteins able to take advantage of strategies used by viruses to infect mammalian cells, aiming to provide new tools for gene therapy and DNA vaccination studies.
机译:基因转移的低效率是DNA疫苗开发和使用非病毒载体(如质粒DNA(pDNA))进行基因治疗研究中的一个经常出现的问题。这主要是由于这样的事实,即质粒载体在运输到靶细胞的核时必须克服一系列物理,酶和扩散障碍。这项工作的主要目的是开发专为pDNA传递而设计的重组蛋白,它利用诸如动力蛋白之类的分子马达将货物从外围运输到哺乳动物细胞的中心体。将DNA结合序列融合至重组人达因轻链LC8的N端。表达研究表明,使用大肠杆菌BL21(DE3)菌株可溶形式正确表达融合蛋白。不出所料,凝胶渗透试验发现纯化的蛋白质主要以二聚体形式存在,即LC8的功能性寡聚状态。凝胶阻滞分析和原子力显微镜证明了融合蛋白与pDNA相互作用和凝聚的能力。 Zeta电位测量结果表明,具有DNA结合域(LD4)的LC8具有增强的相互作用和缩合pDNA的能力,生成带正电荷的复合物。培养的HeLa细胞的转染证实了LD4促进pDNA摄取的能力,并表明逆行转运参与了pDNA:LD4复合物的细胞内转运。最后,细胞毒性研究表明融合蛋白载体的毒性非常低,表明其在体内应用的潜力。本文介绍的研究是开发新的模块化穿梭蛋白的努力的一部分,该蛋白能够利用病毒感染哺乳动物细胞的策略,旨在为基因治疗和DNA疫苗接种研究提供新工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号